Court rules in novel False Claims Act case where one pharma firm sues another viewed by HP&M lawyer
The US District Court for the Central District of California issued a ruling recently in an unusual, if not unprecedented, case arising from alleged federal False Claims Act (FCA) violations where one drug manufacture has sued its competitor, said Delia Stubbs, writing on Hyman, Phelps & McNamara’s FDA Law Blog.
In Amphastar Pharm Inc v Aventis Pharma SA, No 09-0023 (CD Cal), Amphastar, on behalf of the USA, alleged in its amended qui tam complaint that Aventis (now a part of French drug major Sanofi [Euronext: SAN]) had “fraudulently inflated the price of enoxaparin” thus overcharging the federal and various state governments in violation of the FCA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze